Clinical Trial Update: Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older [Phase 3]

View source ↗

Summary

A Phase 3 trial update assessing long-term safety and efficacy of ELX/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor) in cystic fibrosis participants aged 12 months …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ELX/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING